EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Barriers and Facilitators to Pharmacist‐Led Deprescribing of Antihypertensives in Long‐Term Care: A Survey‐Based Study

Ana Vucenovic iD, Roni Y Kraut, Donna P Manca, Cheryl A Sadowski

Basic & Clinical Pharmacology & Toxicology · 2025

DOI: 10.1111/bcpt.70060 ↗

At a glance

Journal article in Basic & Clinical Pharmacology & Toxicology, 2025. Written by Ana Vucenovic and 3 co-authors. Institution: Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada. Major MEDLINE topics: Pharmacists, Antihypertensive Agents, Deprescriptions, Long-Term Care. Cited 3 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Northern Alberta Academic Family Medicine Fund.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pharmacist‐led deprescribing is an approach of addressing polypharmacy in the long‐term care (LTC) setting. However, the sustainability of this practice has not been widely studied. This study describes facilitators and barriers to pharmacist‐led deprescribing from pre‐ and post‐surveys completed as part of a randomized controlled antihypertensive deprescribing trial in Alberta, Canada. The surveys, targeting facilitators and barriers to deprescribing, were developed based on current evidence and designed through an iterative process with pharmacist input and consist of open‐ and closed‐ended questions. Nine pharmacists completed both surveys (seven female; five have been a pharmacist ≥10 years; and eight had their Additional Prescribing Authority [authority to prescribe to full scope of practice]). The key facilitators were (1) pharmacist confidence and attitude toward deprescribing, (2) sufficient patient data, and (3) minimal tools and education required. The key barriers included (1) pharmacist perception of not being the primary decision maker on prescribing decisions, (2) insufficient support from residents' families and physicians, and (3) additional time required. These facilitators and barriers were all identified pre‐deprescribing, and confirmed, and more evident post‐deprescribing. These barriers will make it challenging for pharmacists to incorporate deprescribing antihypertensives into routine care.

Subjects

MeSH terms (MEDLINE)

PharmacistsAntihypertensive AgentsDeprescriptionsLong-Term CarePractice Patterns, Pharmacists'HumansFemaleMaleSurveys and QuestionnairesProfessional RoleAttitude of Health PersonnelPolypharmacyMiddle AgedHypertension

Author keywords

antihypertensivesdeprescribinglong‐term carepharmacistpolypharmacy

Substances

Antihypertensive Agents

Authors and institutions

  • Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.

ORCID profiles: Ana Vucenovic

Funding

  • Northern Alberta Academic Family Medicine Fund

Cite

APA

Vucenovic, A., Kraut, R. Y., Manca, D. P., & Sadowski, C. A. (2025). Barriers and Facilitators to Pharmacist‐Led Deprescribing of Antihypertensives in Long‐Term Care: A Survey‐Based Study. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70060

Vancouver

Vucenovic A, Kraut RY, Manca DP, Sadowski CA. Barriers and Facilitators to Pharmacist‐Led Deprescribing of Antihypertensives in Long‐Term Care: A Survey‐Based Study. Basic & Clinical Pharmacology & Toxicology. 2025. doi:10.1111/bcpt.70060

BibTeX
@article{Vucenovic2025,
  author = {Vucenovic, Ana and Kraut, Roni Y and Manca, Donna P and Sadowski, Cheryl A},
  title = {Barriers and Facilitators to Pharmacist‐Led Deprescribing of Antihypertensives in Long‐Term Care: A Survey‐Based Study},
  journal = {Basic & Clinical Pharmacology & Toxicology},
  year = {2025},
  doi = {10.1111/bcpt.70060}
}
Start for free →